Natural history of COPD exacerbations in a general practice based COPD population
File(s)nh paper 7.0 clean docx.docx (6.64 MB)
Accepted version
Author(s)
Rothnie, kieran
mullerova, hana
smeeth, liam
Quint, JK
Type
Journal Article
Abstract
Rationale: Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are important adverse events in the natural history of chronic obstructive pulmonary disease (COPD).
Objectives: To investigate the natural history of AECOPDs over 10 years of follow-up.
Methods: We identified 99,574 patients with COPD from January 1, 2004, to March 31, 2015, from the UK Clinical Practice Research Datalink. We defined moderate AECOPDs as those managed outside hospital and severe as those requiring hospitalization. During the baseline period (first year of follow-up), patients were grouped according to the number and severity of AECOPDs and then followed for a maximum of 10 years (mean, 4.9 yr). We investigated the effect of baseline AECOPD number and severity on risk of further events and death.
Measurements and Main Results: Around one-quarter of the patients with COPD did not exacerbate during follow-up. Compared with no AECOPDs in the baseline period, AECOPD number predicted the future long-term rate of AECOPDs in a graduated fashion, ranging from hazard ratio (HR) of 1.71 (1.66–1.77) for one event to HR of 3.41 (3.27–3.56) for five or more events. Two or more moderate AECOPDs were also associated with an increased risk of death in a graduated fashion, ranging from HR of 1.10 (1.03–1.18) for two moderate AECOPDs to HR of 1.57 (1.45–1.70) for five or more moderate AECOPDs, compared with those with no AECOPDs at baseline. Severe AECOPDs were associated with an even higher risk of death (HR, 1.79; 1.65–1.94).
Conclusions: A large proportion of patients with COPD do not exacerbate over a maximum 10 years of follow-up. AECOPD frequency in a single year predicts long-term AECOPD rate. Increasing frequency and severity of AECOPDs is associated with risk of death and highlights the importance of preventing AECOPDs.
Objectives: To investigate the natural history of AECOPDs over 10 years of follow-up.
Methods: We identified 99,574 patients with COPD from January 1, 2004, to March 31, 2015, from the UK Clinical Practice Research Datalink. We defined moderate AECOPDs as those managed outside hospital and severe as those requiring hospitalization. During the baseline period (first year of follow-up), patients were grouped according to the number and severity of AECOPDs and then followed for a maximum of 10 years (mean, 4.9 yr). We investigated the effect of baseline AECOPD number and severity on risk of further events and death.
Measurements and Main Results: Around one-quarter of the patients with COPD did not exacerbate during follow-up. Compared with no AECOPDs in the baseline period, AECOPD number predicted the future long-term rate of AECOPDs in a graduated fashion, ranging from hazard ratio (HR) of 1.71 (1.66–1.77) for one event to HR of 3.41 (3.27–3.56) for five or more events. Two or more moderate AECOPDs were also associated with an increased risk of death in a graduated fashion, ranging from HR of 1.10 (1.03–1.18) for two moderate AECOPDs to HR of 1.57 (1.45–1.70) for five or more moderate AECOPDs, compared with those with no AECOPDs at baseline. Severe AECOPDs were associated with an even higher risk of death (HR, 1.79; 1.65–1.94).
Conclusions: A large proportion of patients with COPD do not exacerbate over a maximum 10 years of follow-up. AECOPD frequency in a single year predicts long-term AECOPD rate. Increasing frequency and severity of AECOPDs is associated with risk of death and highlights the importance of preventing AECOPDs.
Date Issued
2018-08-15
Date Acceptance
2018-02-21
Citation
American Journal of Respiratory and Critical Care Medicine, 2018, 198 (4), pp.464-471
ISSN
1073-449X
Publisher
American Thoracic Society
Start Page
464
End Page
471
Journal / Book Title
American Journal of Respiratory and Critical Care Medicine
Volume
198
Issue
4
Copyright Statement
© 2018 by the American Thoracic Soci ety
Sponsor
GlaxoSmithKline Services Unlimited
Grant Number
PO #3000793769
Subjects
Science & Technology
Life Sciences & Biomedicine
Critical Care Medicine
Respiratory System
General & Internal Medicine
epidemiology
cohort studies
case-control studies
COPD
FREQUENCY
CARE
case–control studies
cohort studies
epidemiology
Aged
Case-Control Studies
Disease Progression
Female
Follow-Up Studies
General Practice
Humans
Male
Pulmonary Disease, Chronic Obstructive
Severity of Illness Index
United Kingdom
Humans
Pulmonary Disease, Chronic Obstructive
Disease Progression
Severity of Illness Index
Case-Control Studies
Follow-Up Studies
Aged
Female
Male
General Practice
United Kingdom
11 Medical and Health Sciences
Respiratory System
Publication Status
Published
Date Publish Online
2018-02-23